http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
POOJAN SHIV,배승현,Jae-Woong Min,이은영,송유라,Kim Hee Yeon,심혜원,Kang Eun-Kyung,김영호,Hae-Ock Lee,Hong Yourae,Woong-Yang Park,장현철,홍경만 생화학분자생물학회 2020 Experimental and molecular medicine Vol.52 No.-
To elucidate the epigenetic mechanisms of drug resistance, epigenetically reprogrammed H460 cancer cells (R-H460) were established by the transient introduction of reprogramming factors. Then, the R-H460 cells were induced to differentiate by the withdrawal of stem cell media for various durations, which resulted in differentiated R-H460 cells (dR-H460). Notably, dR-H460 cells differentiated for 13 days (13dR-H460 cells) formed a significantly greater number of colonies showing drug resistance to both cisplatin and paclitaxel, whereas the dR-H460 cells differentiated for 40 days (40dR-H460 cells) lost drug resistance; this suggests that 13dR-cancer cells present short-term resistance (less than a month). Similarly, increased drug resistance to both cisplatin and paclitaxel was observed in another R-cancer cell model prepared from N87 cells. The resistant phenotype of the cisplatin-resistant (CR) colonies obtained through cisplatin treatment was maintained for 2–3 months after drug treatment, suggesting that drug treatment transforms cells with short-term resistance into cells with medium-term resistance. In single-cell analyses, heterogeneity was not found to increase in 13dR-H460 cells, suggesting that cancer cells with short-term resistance, rather than heterogeneous cells, may confer epigenetically driven drug resistance in our reprogrammed cancer model. The epigenetically driven short-term and medium-term drug resistance mechanisms could provide new cancer-fighting strategies involving the control of cancer cells during epigenetic transition.
Ovarian Torsion in a Postmenopausal Woman: A Case Report and Review of Literature
Marwaha Poojan Dogra,Kaundal Asmita,Bhavna,Malik Nisha,Kaushal Sushruti 대한폐경학회 2023 대한폐경학회지 Vol.29 No.3
Postmenopausal ovarian masses are not uncommon. Most of them are malignant due to inflammation and adhesion with the surrounding structures; these masses are fixed and torsion is not a usual phenomenon. We present a 73-year-old postmenopausal woman, parity five and five living issues with an acute abdomen. The examination revealed a 28–30-week size abdominal pelvic mass, which was confirmed to be ovarian in origin, with characteristics that indicated torsion on ultrasound Doppler. She underwent an emergency laparotomy with a total abdominal hysterectomy and bilateral salpingo-ophrectomy. Histopathology confirmed the diagnosis of serous cystadenoma. Ovarian torsion is a crucial differential diagnosis in postmenopausal adnexal masses presenting with acute abdomen. A high index of suspicion is required to diagnose and promptly manage women to improve the outcome.
김영우,Young-Ho Kim,송유라,Han-Seong Kim,심혜원,Shiv Poojan,엄방울,Myeong-Cherl Kook,주정남,홍경만 생화학분자생물학회 2019 Experimental and molecular medicine Vol.51 No.-
Circulating tumor DNA (ctDNA) has emerged as a candidate biomarker for cancer screening. However, studies on the usefulness of ctDNA for postoperative recurrence monitoring are limited. The present study monitored ctDNA in postoperative blood by employing cancer-specific rearrangements. Personalized cancer-specific rearrangements in 25 gastric cancers were analyzed by whole-genome sequencing (WGS) and were employed for ctDNA monitoring with blood up to 12 months after surgery. Personalized cancer-specific rearrangements were identified in 19 samples. The median lead time, which is the median duration between a positive ctDNA detection and recurrence, was 4.05 months. The presence of postoperative ctDNA prior to clinical recurrence was significantly correlated with cancer recurrence within 12 months of surgery (P = 0.029); in contrast, no correlation was found between cancer recurrence and the presence of preoperative ctDNA, suggesting the clinical usefulness of postoperative ctDNA monitoring for cancer recurrence in gastric cancer patients. However, the clinical application of ctDNA can be limited by the presence of ctDNA non-shedders (42.1%, 8/19) and by inconsistent postoperative ctDNA positivity.
Chandra, Vishal,Choi, Yong-Bock,Hwang, Hai-Li,Lee, Jeong-Hwa,Park, Seong-Yeol,Kim, Hyun-Kyoung,Poojan, Shiv,Koh, Jae-Soo,Kim, Han-Seong,Hong, Kyeong-Man Gutenberg 2015 HISTOLOGY AND HISTOPATHOLOGY Vol.30 No.9
<P>We have shown both LLC1 expression in the lung epithelium by in situ hybridization and its inactivation in lung cancer by epigenetic modification. However, LLC1 protein's cellular localization or its role in normal lung or cancer tissues has not yet been evaluated. In the present study, a monoclonal antibody against recombinant LLC1 was produced, and immunohistochemical staining was performed on arrays including various human tissues, normal lung and non-small cell lung cancer (NSCLC) tissues for LLC1 localization. The immunohistochemical results showed LLC1 expression in the cilia of normal-airway epithelial cells and in the cytoplasm of type II pneumocytes in bronchiectatic patients, but no expression in most of the NSCLC tissues, which is consistent with our previous report positing LLC1 as a tumor suppressor. However, LLC1 over-expression in NSCLC cell lines NCI-H1299 and NCI-H23 did not show any change in proliferation or migration, which does not indicate any LLC1 tumor-suppressor role. As for the other human tissues, LLC1 was localized in renal tubular cells, pancreatic acinar cells, and epithelial cells of the stomach, duodenum, and gallbladder. In summary, our findings suggest that LLC1 is not a tumor suppressor, and that it is localized in the cilia of the normal lung epithelium but is absent in most NSCLC cases, probably due to the loss of cilia during lung carcinogenesis.</P>
Clinical implications of proliferation activity in T1 or T2 male gastric cancer patients
김영우,엄방울,Myeong-Cherl Kook,김한성,김미경,Hai-Li Hwang,Vishal Chandra,Shiv Poojan,송유라,고재수,배창대,노정실,홍경만 생화학분자생물학회 2015 Experimental and molecular medicine Vol.47 No.-
Proliferation activity has already been established as a prognostic marker or as a marker for anticancer drug sensitivity. In gastric cancer, however, the prognostic significance of proliferation activity is still being debated. Several studies evaluating proliferation activity using Ki-67 have shown controversial results in terms of the relationship between proliferation activity and overall survival (OS) or drug sensitivity in gastric cancer patients. Because cytoskeleton-associated protein 2 (CKAP2) staining has recently been introduced as a marker of proliferation activity, we analyzed 437 gastric cancer tissues through CKAP2 immunohistochemistry, and we evaluated the chromatin CKAP2-positive cell count (CPCC) for proliferation activity. Although the CPCC did not show any significant correlation with OS in the male, female or total number of cases, it did show a significant correlation in the T1 or T2 male patient subgroup, according to log-rank tests (P=0.001) and univariate analysis (P=0.045). Additionally, multivariate analysis with the Cox proportional hazard regression model showed a significant correlation between the CPCC and OS (P=0.039) for the co-variables of age, gender, T stage, N stage, histology, tumor location, tumor size and adjuvant chemotherapy. In male gastric cancer cell lines, faster-growing cancer cells showed higher sensitivity to cisplatin than slow-growing cells. Thus our study indicates that CPCC-measured proliferation activity demonstrates a significantly worse prognosis in T1 or T2 male gastric cancer patients. The CPCC will help to more precisely classify gastric cancer patients and to select excellent candidates for adjuvant chemotherapy, which in turn will facilitate further clinical chemotherapeutic trials.
Clinical implications of proliferation activity in T1 or T2 male gastric cancer patients
Kim, Young-Woo,Eom, Bang Wool,Kook, Myeong-Cherl,Kim, Han-Seong,Kim, Mi-Kyung,Hwang, Hai-Li,Chandra, Vishal,Poojan, Shiv,Song, Yura,Koh, Jae-Soo,Bae, Chang-Dae,Ro, Jungsil,Hong, Kyeong-Man Nature Publishing Group 2015 Experimental and molecular medicine Vol.47 No.11
<P>Proliferation activity has already been established as a prognostic marker or as a marker for anticancer drug sensitivity. In gastric cancer, however, the prognostic significance of proliferation activity is still being debated. Several studies evaluating proliferation activity using Ki-67 have shown controversial results in terms of the relationship between proliferation activity and overall survival (OS) or drug sensitivity in gastric cancer patients. Because cytoskeleton-associated protein 2 (CKAP2) staining has recently been introduced as a marker of proliferation activity, we analyzed 437 gastric cancer tissues through CKAP2 immunohistochemistry, and we evaluated the chromatin CKAP2-positive cell count (CPCC) for proliferation activity. Although the CPCC did not show any significant correlation with OS in the male, female or total number of cases, it did show a significant correlation in the T1 or T2 male patient subgroup, according to log-rank tests (<I>P</I>=0.001) and univariate analysis (<I>P</I>=0.045). Additionally, multivariate analysis with the Cox proportional hazard regression model showed a significant correlation between the CPCC and OS (<I>P</I>=0.039) for the co-variables of age, gender, T stage, N stage, histology, tumor location, tumor size and adjuvant chemotherapy. In male gastric cancer cell lines, faster-growing cancer cells showed higher sensitivity to cisplatin than slow-growing cells. Thus our study indicates that CPCC-measured proliferation activity demonstrates a significantly worse prognosis in T1 or T2 male gastric cancer patients. The CPCC will help to more precisely classify gastric cancer patients and to select excellent candidates for adjuvant chemotherapy, which in turn will facilitate further clinical chemotherapeutic trials.</P>